Tim Simon, MD
Family Medicine · Monticello, ARNPI 1376523316
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 318 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,325 and has fallen 77.6% since, to $297 in 2025.
Across 318 payments — averaging $13.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$698
- GSK$496
- AstraZeneca$418
- Amgen$399
- Pfizer$357
- Takeda Pharmaceuticals U.S.A., Inc.$301
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,37299%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $698 |
| GSK | 39 | $496 |
| AstraZeneca | 20 | $418 |
| Amgen(2 entities) | 34 | $399 |
| Pfizer | 35 | $357 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $301 |
| Novo Nordisk | 17 | $259 |
| Merck | 19 | $258 |
| E.r. Squibb & Sons, L.L.C. | 10 | $137 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $83 |
| Astellas Pharma US Inc | 6 | $79 |
| Biohaven Pharmaceuticals, Inc. | 5 | $77 |
| Novartis | 6 | $76 |
| Boehringer Ingelheim | 5 | $73 |
| Sunovion Pharmaceuticals Inc. | 5 | $62 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $56 |
| Johnson & Johnson | 4 | $54 |
| Dexcom, Inc. | 3 | $53 |
| Bayer | 3 | $51 |
| Esperion Therapeutics, Inc. | 4 | $49 |
| Supernus Pharmaceuticals, Inc. | 3 | $46 |
| Shield Therapeutics Inc | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Abbott | 2 | $27 |
| United Therapeutics Corporation | 1 | $26 |
| Lilly USA, LLC | 2 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Insulet Corporation | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$132
How this compares
$4,412 in reported general payments places this provider in the 85th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,198 | $642,221 |
| OzempicSemaglutide | 358 | $362,012 |
| XareltoRivaroxaban | 337 | $180,502 |
| MounjaroTirzepatide | 131 | $144,477 |
| JardianceEmpagliflozin | 294 | $131,247 |
| FarxigaDapagliflozin Propanediol | 141 | $97,883 |
| JanuviaSitagliptin Phosphate | 188 | $90,375 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $87,529 |
| EntrestoSacubitril/Valsartan | 136 | $82,608 |
| LinzessLinaclotide | 103 | $71,231 |
| Tresiba Flextouch U-100Insulin Degludec | 91 | $53,782 |
| MyrbetriqMirabegron | 99 | $52,287 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $42,321 |
| XifaxanRifaximin | 13 | $40,073 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 341 | $39,263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $357 | $642,2211,198 claims |
| Novo NordiskOzempic | $259 | $362,012358 claims |
| Johnson & JohnsonXarelto | $54 | $180,502337 claims |
| Lilly USA, LLCMounjaro, Trulicity | $22 | $168,304157 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $496 | $157,224233 claims |
| Boehringer IngelheimJardiance, Tradjenta | $73 | $143,530317 claims |
| AstraZenecaFarxiga, Symbicort | $418 | $133,254259 claims |
| MerckJanuvia | $258 | $90,375188 claims |
| AbbVieLinzess, Creon | $698 | $90,305116 claims |
| NovartisEntresto | $76 | $82,608136 claims |
| Astellas Pharma US IncMyrbetriq | $79 | $52,28799 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $83 | $40,07313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Monticello
- Glenn GibbonsFort Smith$179K
- Hetal PatelParagould$147K
- David GersonSherwood$119K
- Scott MusickBentonville$102K
- Broderick EatonWynne$49K
- Craig LevoyBentonville$30K
- Allen BeachyFort Smith$21K
- Hunter CarringtonHot Springs$20K
- Harold BettonLittle Rock$18K
- Thad HardinConway$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.